Welcome to our dedicated page for Alphatec Holdings news (Ticker: $ATEC), a resource for investors and traders seeking the latest updates and insights on Alphatec Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alphatec Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alphatec Holdings's position in the market.
Alphatec Holdings, Inc. (Nasdaq: ATEC) reported a 27% growth in total revenue to $138 million, with 30% increase in surgical revenue. Adjusted EBITDA margin expanded by 450 basis points. Full-year revenue and adjusted EBITDA guidance raised to $601 million and $23 million respectively. The company experienced growth in surgical revenue, surgeon adoption, and U.S. footprint expansion. Ending cash balance was $144 million. Non-GAAP gross margin was 71%. The CEO expressed confidence in the company's future growth potential.
Alphatec Holdings, Inc. (Nasdaq: ATEC) will be participating in several investor conferences in May and June 2024. The company also granted 14,024 restricted stock units to new employees as an inducement to accepting employment, which will vest in equal annual installments on each of the first four anniversaries of the grant date, contingent on the recipient's continuous employment with ATEC.